Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial

Hepatology

Volumn 62, Issue 2, 2015, Pages 567-574

  Cavallin, Marta ^a   Kamath, Patrick S ^b   Merli, Manuela ^c   Fasolato, Silvano ^a   Toniutto, Pierluigi ^d   Salerno, Francesco ^e   Bernardi, Mauro ^f   Romanelli, Roberto Giulio ^g   Colletta, Cosimo ^h   Salinas, Freddy ⁱ   Di Giacomo, Antonio ^j   Ridola, Lorenzo ^c   Fornasiere, Ezio ^d   Caraceni, Paolo ^f   Morando, Filippo ^a   Piano, Salvatore ^a   Gatta, Angelo ^a   Angeli, Paolo ^a,k  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b MAYO CLINIC   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h Hospital of Verbania   (Italy)

ⁱ Private Hospital Giovanni XXIII of Monastier   (Italy)

^j Department of Pediatrics   (Italy)

^k UNIVERSITY OF PADOVA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; MIDODRINE; OCTREOTIDE; TERLIPRESSIN; ALBUMINOID; LYPRESSIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HEART VENTRICLE OVERLOAD; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; DRUG COMBINATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MORTALITY; PREDICTIVE VALUE; SURVIVAL; TREATMENT OUTCOME;

AGED; ALBUMINS; ANALYSIS OF VARIANCE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATORENAL SYNDROME; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; LYPRESSIN; MALE; MIDDLE AGED; MIDODRINE; OCTREOTIDE; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84938201035     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27709     Document Type: Article

References (28)

1. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48(Suppl. 1):S93-S103.
2. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-176.
3. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
4. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318.
5. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8(5):1151-1157.
6. Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 2011;17:1328-1332.
7. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004;40:140-146.
8. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-1697.
9. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-380.
10. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
11. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007;47:499-505.
12. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689-1697.
13. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012;56:1293-1298.
14. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279-1290.
15. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359.
16. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008;53:830-835.
17. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368.
18. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576-584.
19. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
20. Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation 2011;91:1141-1147.
21. Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009;43:680-685.
22. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52:742-748.
23. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
24. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2011;55:315-321.
25. Nazar A, Pereira GH, Guevara M, Martin-Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010;51:219-226.
26. Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis 2011;58:928-938.
27. Escorsell A, Bandi JC, Moitinho E, Feu F, Garcia-Pagan JC, Bosch J, et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997;26:621-627.
28. Rodrìguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, et al. Terlipressin and albumin for type 1 hepatorenal syndrome associated with sepsis. J Hepatol 2014;60:955-961.